Literature DB >> 27122103

Re-expansion pulmonary oedema: a novel emergency therapeutic option.

Nicholas Sunderland1, Robert Maweni1, Srikanth Akunuri1, Elena Karnovitch1.   

Abstract

Re-expansion pulmonary oedema (REPO) is a rare complication of pleural fluid thoracocentesis and has been associated with a high mortality rate. There is limited evidence to inform on its most effective management. We present two cases of large volume thoracocentesis resulting in acute respiratory decompensation that was treated by reintroducing the drained pleural fluid back into the pleural cavity. We also present a review of the literature specifically assessing the reported incidence rate of REPO after pleural fluid drainage. In both of our cases, symptoms and signs of respiratory instability were promptly reversed on reintroduction of the drained pleural fluid into the patient's pleural space-a therapy we have termed 'rapid pleural space re-expansion'. This was not associated with any short-term adverse outcomes. The occurrence of REPO is a rare event with most cohort studies reporting an incidence of between 0% and 1%. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 27122103      PMCID: PMC4854158          DOI: 10.1136/bcr-2016-215076

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

1.  Point: should pleural manometry be performed routinely during thoracentesis? Yes.

Authors:  David Feller-Kopman
Journal:  Chest       Date:  2012-04       Impact factor: 9.410

2.  Counterpoint: should pleural manometry be performed routinely during thoracentesis? No.

Authors:  Fabien Maldonado; John J Mullon
Journal:  Chest       Date:  2012-04       Impact factor: 9.410

Review 3.  Reexpansion pulmonary edema.

Authors:  Yasunori Sohara
Journal:  Ann Thorac Cardiovasc Surg       Date:  2008-08       Impact factor: 1.520

4.  Experimental pulmonary edema following re-expansion of pneumothorax.

Authors:  W C Miller; R Toon; H Palat; J Lacroix
Journal:  Am Rev Respir Dis       Date:  1973-09

5.  Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion.

Authors:  Carolyn M Dresler; Jemi Olak; James E Herndon; William G Richards; Ernest Scalzetti; Stewart B Fleishman; Kemp H Kernstine; Todd Demmy; David M Jablons; Leslie Kohman; Thomas M Daniel; George B Haasler; David J Sugarbaker
Journal:  Chest       Date:  2005-03       Impact factor: 9.410

6.  Focal reexpansion pulmonary edema after drainage of large pleural effusions: clinical evidence suggesting hypoxic injury to the lung as the cause of edema.

Authors:  J H Woodring
Journal:  South Med J       Date:  1997-12       Impact factor: 0.954

7.  Impact of pleural manometry on the development of chest discomfort during thoracentesis: a symptom-based study.

Authors:  Jasleen Pannu; Zachary S DePew; John J Mullon; Craig E Daniels; Clinton E Hagen; Fabien Maldonado
Journal:  J Bronchology Interv Pulmonol       Date:  2014-10

8.  Unilateral pulmonary edema in rabbits after reexpansion of collapsed lung.

Authors:  J Pavlin; F W Cheney
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1979-01

9.  The clinical case report: a review of its merits and limitations.

Authors:  Trygve Nissen; Rolf Wynn
Journal:  BMC Res Notes       Date:  2014-04-23

10.  Contralateral reexpansion pulmonary edema with ipsilateral collapsed lung after pleural effusion drainage: a case report.

Authors:  Jae Jun Kim; Yong Hwan Kim; Si Young Choi; Seong Cheol Jeong; Seok Whan Moon
Journal:  J Cardiothorac Surg       Date:  2015-05-08       Impact factor: 1.637

View more
  2 in total

1.  Lessons from fatal re-expansion pulmonary oedema: case series.

Authors:  Dambuza Nyamande; Siphosenkosi Mazibuko
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-06-01

Review 2.  Research Progress on the Mechanism of Right Heart-Related Pulmonary Edema.

Authors:  Yiran Li; Xiaoqiang Wang; Ruiqing Zong; Feixiang Wu; Hai Lin
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-03       Impact factor: 2.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.